Skip to main content

Brooklyn ImmunoTherapeutics, Inc. (BTX)

NYSEAMERICAN: BTX · Delayed Price · USD
9.65
+0.03 (0.31%)
After-hours:Oct 21, 2021 7:13 PM EDT
9.62
-0.11 (-1.13%)
At close: Oct 21, 4:00 PM
Market Cap503.33M
Revenue (ttm)2.65M
Net Income (ttm)-28.98M
Shares Out42.45M
EPS (ttm)-1.66
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume447,058
Open9.76
Previous Close9.73
Day's Range9.60 - 10.10
52-Week Range3.50 - 80.67
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 11, 2021

About BTX

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.

IndustryBiotechnology
Founded2018
Employees2,018
Stock ExchangeNYSEAMERICAN
Ticker SymbolBTX
Full Company Profile

Financial Performance

In 2020, BTX's revenue was $5.80 million, a decrease of -70.72% compared to the previous year's $19.81 million. Losses were -$4.42 million, 115.7% more than in 2019.

Financial Statements

News

Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq

Ticker Symbol to Remain “BTX” Ticker Symbol to Remain “BTX”

1 week ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Reports Inducement Grants

NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing...

4 weeks ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer

NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editin...

4 weeks ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021

NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing...

1 month ago - GlobeNewsWire

Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Mass...

CAMBRIDGE, Mass., Sept. 15, 2021 /PRNewswire/ -- Factor Bioscience Inc., a biotechnology company headquartered in Cambridge, Massachusetts, celebrated its tenth anniversary on September 9, 2021 with the...

1 month ago - PRNewsWire

Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Monday, September 20, 2021, at 4:30 PM ET

BROOKLYN, N.Y., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene e...

1 month ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum

BROOKLYN, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene ed...

2 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from August 19, 2021

NEW YORK, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/...

2 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Thursday, August 19, 2021 at 4:30 PM ET

BROOKLYN, N.Y., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene ed...

2 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Announces Second Quarter 2021 Financial Results

NEW YORK, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that gene editing/cell and cyto...

2 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics to Present at the SNN Virtual Investor Conference on August 18, 2021

NEW YORK, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/...

2 months ago - GlobeNewsWire

Brooklyn Immuno Reports Inducement Grants

BROOKLYN, N.Y., July 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene ed...

2 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics

Acquisition Advances Transformation Into Platform Company Focused on Cell, Gene Editing and Cytokine Therapy

3 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer

NEW YORK, July 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/...

3 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021

NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that cytokine an...

3 months ago - GlobeNewsWire

7 Top-Rated Pharmaceutical Companies to Invest In for July

Pharma stocks like MNMD stock and ANVS stock offer investors long-term growth potential in a market on track to hit a value of $1.70 trillion. The post 7 Top-Rated Pharmaceutical Companies to Invest In ...

3 months ago - InvestorPlace

Brooklyn ImmunoTherapeutics Reports Inducement Grants

NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that cytokine an...

3 months ago - GlobeNewsWire

7 Best Reddit Stocks to Buy If You Have $100 to Spare

Looking to roll the dice? Consider buying one (or more) of these seven high-risk, but possibly high-return, Reddit stocks.

4 months ago - InvestorPlace

Why Brooklyn ImmunoTherapeutics Crushed the Market Today

The biotech is bulking up with a new acquisition.

4 months ago - The Motley Fool

Brooklyn ImmunoTherapeutics Stock Rises After Novellus Therapeutics Buyout Deal

Brooklyn ImmunoTherapeutics LLC (NYSE: BTX) has executed a non-binding letter of intent to acquire Novellus Therapeutics, a company developing engineered mesenchymal stem cell (MSC) therapies using mRNA...

4 months ago - Benzinga

Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics

Novellus Therapeutics develops next-generation mesenchymal stem cell products using licensed patented mRNA cell reprogramming and gene editing technologies Novellus Therapeutics develops next-generation...

4 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Set to Join Russell 3000 Index

BROOKLYN, N.Y., June 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene ed...

4 months ago - GlobeNewsWire

Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D'Amour as Chief Scientific Officer

BROOKLYN, N.Y., June 08, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene ed...

4 months ago - GlobeNewsWire

Brooklyn Immunotherapeutics Stock Is a Worthy Bet on Genetics Research

BTX stock holders will certainly want to brace for volatility. Still, the outlook's bullish as the company pursues its game-changing research.

4 months ago - InvestorPlace

Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company's Future During May 25, 2021 Shar...

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company's Future During May 25, 2021 Shareholder Update Call

4 months ago - Business Wire